AprilBio Co.,Ltd.

397030· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩25,400+6.28%

2026-08-04

Financials

Valuation Metrics

AprilBio Co.,Ltd.'s Market Cap is ₩5947B. At end of 2025 it was ₩1.3T. Ranked #399 of 2,436 in KR market (top 16%), #132 of 1,649 on KOSDAQ (top 8%), #44 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	594.71B KRW	KR#399/2,436 Sec#44/234
Revenue	725.4M KRW	KR#2,394/2,436 Sec#221/234
Net Income	-10.12B KRW	KR—/2,436 Sec—/234
Total Assets	98.88B KRW	KR#1,751/2,436 Sec#142/234
Net Assets	97.90B KRW	KR#1,414/2,436 Sec#116/234
Employees	26	KR#2,194/2,436 Sec#203/234
Value
P/B	6.08x	KR#2,274/2,436 Sec#192/234
P/S	819.90x	KR#2,411/2,436 Sec#225/234
Profitability
ROE	-10.34%	KR#1,905/2,436 Sec#148/234
ROA	-10.24%	KR#2,082/2,436 Sec#161/234
Op. Margin	-1288.55%	KR#2,390/2,436 Sec#218/234
Revenue Growth	-66.60%	KR#2,324/2,436 Sec#206/234
Earnings Growth	-66.14%	KR#1,270/2,436 Sec#83/234
Financial Health
Debt Ratio	101.01%	KR#326/2,436 Sec#41/234
Total Debt	0 KRW	KR—/2,436 Sec—/234
Cash	6.43B KRW	KR#1,897/2,436 Sec#166/234
Current Ratio	110.34x	KR#1/2,436 Sec#1/234
Performance
1Y Return	27.25%	KR#361/2,436 Sec#33/234
1M Return	-22.32%	KR#2,258/2,436 Sec#223/234
From 52W High	-66.88%	KR#2,032/2,436 Sec#176/234
1Y MDD	-73.41%	KR#2,081/2,436 Sec#186/234
Trading
Volume	411,237 shares	KR#321/2,436 Sec#38/234
Foreign Own.	13.38%	KR#370/2,436 Sec#29/234
Per Share
EPS	-442 KRW	KR—/2,436 Sec—/234
BPS	4,194 KRW	KR#1,582/2,436 Sec#120/234

Company Info

CEO 차상훈

Employees 26

Founded 2013

HQ 강원도 춘천시, KR

Website www.aprilbio.com/

동사는 2013년 교원창업 형태로 설립된 연구개발 중심 기업임. HuDVFab library와 SAFA 플랫폼을 보유하고, 이를 기반으로 항체치료제, 이중항체, 지속형 재조합 단백질 의약품 등을 개발하고 있음. 자가면역질환, 염증질환, 암, 희귀질환을 목표로 신약 후보물질을 발굴하고 글로벌 기술이전을 통해 수익을 창출하는 RIPCO 모델을 운영하며, 장기적으로 FIPCO 모델로의 전환을 계획하고 있음. 에이프릴바이오는 2013년에 설립되었으며 강원도 춘천시에 본사를 두고 있습니다.